Related Experiment Video
Updated: Apr 26, 2026
09:53
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
7.2K
A micro RNA-146a polymorphism is associated with coronary restenosis
L Hamann1, C Glaeser, S Schulz
1Institute of Microbiology and Hygiene, Charité University Medical Center, Berlin, Germany.
International Journal of Immunogenetics
|July 24, 2014
Summary
The miRNA-146a rs2910164 polymorphism is not linked to atherosclerosis. However, specific genotypes (G/C and C/C) were associated with increased restenosis risk after cardiac surgery.
Area of Science:
- Genetics and Cardiovascular Disease
- Molecular Biology
- Biomarkers
Background:
- Atherosclerosis and restenosis pose significant challenges in cardiovascular medicine.
- MicroRNAs (miRNAs) play crucial roles in regulating cellular processes relevant to cardiovascular health.
- The miRNA-146a gene, specifically the rs2910164 polymorphism, is a potential factor influencing these conditions.
Purpose of the Study:
- To investigate the association between the miRNA-146a polymorphism rs2910164 and the risk of atherosclerosis.
- To examine the relationship between the miRNA-146a polymorphism rs2910164 and the risk of restenosis following cardiac surgery.
Main Methods:
- Genotyping of the miRNA-146a rs2910164 polymorphism in a relevant patient cohort.
- Statistical analysis to determine the association between genotypes and the incidence of atherosclerosis and restenosis.
Main Results:
- No significant association was found between the miRNA-146a rs2910164 polymorphism and atherosclerosis.
- A negative association was observed for the G/C genotype (P = 0.007) with restenosis risk.
- A positive association was observed for the C/C genotype with an increased risk of restenosis.
Conclusions:
- The miRNA-146a rs2910164 polymorphism is not associated with atherosclerosis.
- Specific genotypes of miRNA-146a rs2910164 (G/C and C/C) are significantly associated with the risk of developing restenosis after cardiac surgery.
- This polymorphism may serve as a predictive biomarker for restenosis risk in patients undergoing cardiac procedures.
Related Concept Videos
01:22MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
01:22MicroRNAs
20.9K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
20.9K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
156
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156